Trial Profile
A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule or Administered at a High Titre as a 3 Dose Infant Schedule.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Rotavirus vaccine (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- 20 Aug 2020 Status changed from active, no longer recruiting to completed.
- 26 Feb 2020 Planned End Date changed from 1 Mar 2020 to 1 Jul 2020.
- 26 Feb 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jul 2020.